Similarly, the logistic regression model with GEE evaluating the probability of being seizure-free during the follow-up visits showed a borderline significance difference between the two treatment arms ( Table 6 ).
← all excerpts
Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial.
1
—
—